Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BION-1301 in Relapsed/Refractory Multiple Myeloma
NCT03340883Phase 2Terminated
- Sponsor
- Chinook Therapeutics
- Start
- Nov 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zigakibart in multiple myeloma (MM), sponsored by Chinook Therapeutics. Started Nov 2017; status: terminated.
02
Drugs
zigakibart
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03340883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03340883.